Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP & Chief Financial Officer | March 19, 2018 | March 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date March 19, 2018 · Filed March 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,762 |
Ending reported balance
After 2018-03-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-03-19 · Sale · Disposed 3,000 · Balance 91,762 F1: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.90 to $42.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2018-03-20 · Sale · Disposed 3,000 · Balance 88,762 F1: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.90 to $42.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2018 Filed Mar 20, 2018 18:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,000 | $38.83 | $116,490.00 |
DisclosureSEC source: 0001209191-18-020971 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,762 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 18:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,000 | $41.99 | $125,970.00 |
DisclosureSEC source: 0001209191-18-020971 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,762 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.90 to $42.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $48.08 | $120,200.00 |
DisclosureSEC source: 0001209191-18-011664 · doc4.xml · nonDerivative · entry 5 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,762 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F6 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.70 to $48.325. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,000 | $46.93 | $187,720.00 |
DisclosureSEC source: 0001209191-18-011664 · doc4.xml · nonDerivative · entry 4 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,262 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F5 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.65 to $47.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 5,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011664 · doc4.xml · derivative · entry 6 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,132 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F8 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F9 · derivative.exercise_date: Fully vested. F10 · derivative.expiration_date: The earlier of (i) December 12, 2020 or (ii) the recipient's termination date. F11 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 2,926 | $47.05 | $137,668.30 |
DisclosureSEC source: 0001209191-18-011664 · doc4.xml · nonDerivative · entry 3 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,262 F4 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 5,132 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-011664 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 20:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,500 | $46.77 | $304,005.00 |
DisclosureSEC source: 0001209191-18-011664 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,056 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.50 to $47.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 20:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,819 | $41.70 | $200,952.30 |
DisclosureSEC source: 0001209191-18-009405 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,556 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-18-008508 · doc4.xml · derivative · entry 3 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-02-06 F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,279 | $35.80 | $153,188.20 |
DisclosureSEC source: 0001209191-18-008508 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,375 F2 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 17:43 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008508 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,654 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003485 · doc4.xml · derivative · entry 5 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 30,000 shares Expires 2021-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F5 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 30,000 | $25.00 | $750,000.00 |
DisclosureSEC source: 0001209191-18-003485 · doc4.xml · nonDerivative · entry 4 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,654 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.025. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $22.32 | $78,120.00 |
DisclosureSEC source: 0001209191-18-003485 · doc4.xml · nonDerivative · entry 3 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,654 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.15 to $22.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 30,000 | $11.00 | $330,000.00 |
DisclosureSEC source: 0001209191-18-003485 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 19:56 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $20.77 | $72,695.00 |
DisclosureSEC source: 0001209191-18-003485 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,154 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.70 to $20.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 19:14 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 32,000 | $20.00 | $640,000.00 |
DisclosureSEC source: 0001209191-18-000376 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,654 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 7,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061602 · doc4.xml · derivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,132 Underlying: Common Stock · 7,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) December 12, 2020 or (ii) the recipient's termination date. F5 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 18:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-061602 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| August 16, 2017 Filed Aug 17, 2017 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,100 | $14.39 | $30,219.00 |
DisclosureSEC source: 0001209191-17-049449 · doc4.xml · nonDerivative · entry 3 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,957 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.05 to $14.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 7,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049449 · doc4.xml · derivative · entry 4 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,829 Underlying: Common Stock · 7,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) December 12, 2020 or (ii) the recipient's termination date. F8 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,100 | $14.23 | $29,883.00 |
DisclosureSEC source: 0001209191-17-049449 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,057 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.20 to $14.275. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 17:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-049449 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| May 16, 2017 Filed May 17, 2017 17:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,000 | $15.27 | $30,540.00 |
DisclosureSEC source: 0001209191-17-033208 · doc4.xml · nonDerivative · entry 4 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,460 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F4 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.20 to $15.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 7,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033208 · doc4.xml · derivative · entry 6 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,526 Underlying: Common Stock · 7,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F9 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F10 · derivative.expiration_date: The earlier of (i) December 12, 2020 or (ii) the recipient's termination date. F8 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 935 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033208 · doc4.xml · derivative · entry 5 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 935 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 13, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) March 13, 2020 or (ii) the recepient's termination date. F8 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,000 | $14.95 | $29,900.00 |
DisclosureSEC source: 0001209191-17-033208 · doc4.xml · nonDerivative · entry 3 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,460 F2 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.70 to $15.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033208 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:01 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 935 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033208 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| March 23, 2017 Filed Mar 23, 2017 20:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,500 | $21.08 | $137,020.00 |
DisclosureSEC source: 0001209191-17-022684 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,827 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.80 to $21.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 22, 2017 Filed Mar 23, 2017 20:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,500 | $20.27 | $152,025.00 |
DisclosureSEC source: 0001209191-17-022684 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,327 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.10 to $20.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 19:57 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 24,000 | $20.00 | $480,000.00 |
DisclosureSEC source: 0001209191-17-019981 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,827 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 17:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,000 | $15.14 | $136,260.00 |
DisclosureSEC source: 0001209191-17-013442 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,827 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.90 to $15.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 7,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011768 · doc4.xml · derivative · entry 4 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 28,224 Underlying: Common Stock · 7,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) December 12, 2020 or (ii) the recipient's termination date. F5 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011768 · doc4.xml · derivative · entry 3 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 935 Underlying: Common Stock · 2,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 13, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 13, 2020 or (ii) the recepient's termination date. F5 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011768 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 20:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 2,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-011768 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 17:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 49,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008827 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,326 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 7,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150916 · doc4.xml · derivative · entry 4 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 35,921 Underlying: Common Stock · 7,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F6 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F7 · derivative.expiration_date: The earlier of (i) December 12, 2020 or (ii) the recipient's termination date. F5 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionRestricted Stock Units · Derivative | 2,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150916 · doc4.xml · derivative · entry 3 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,739 Underlying: Common Stock · 2,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement. F3 · derivative.exercise_date: The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on March 13, 2014 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date. F4 · derivative.expiration_date: The earlier of (i) March 13, 2020 or (ii) the recepient's termination date. F5 · ownership.nature: The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 7,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150916 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 16:53 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 2,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-150916 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares issued upon settlement of vested restricted stock units ("RSUs"). Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 16:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $19.37 | $48,425.00 |
DisclosureSEC source: 0001209191-16-149731 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,323 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.30 to $19.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 16:45 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $20.30 | $50,750.00 |
DisclosureSEC source: 0001209191-16-149731 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,823 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.55 to $21.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 12, 2016 Filed Oct 13, 2016 17:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $16.41 | $41,025.00 |
DisclosureSEC source: 0001209191-16-145821 · doc4.xml · nonDerivative · entry 2 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,323 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $16.35 to $16.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 17:22 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,500 | $18.52 | $46,300.00 |
DisclosureSEC source: 0001209191-16-145821 · doc4.xml · nonDerivative · entry 1 MCGRATH JOHN · CIK 0001205442 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,823 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.30 to $18.675. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.